ACTIVE WATCHFUL WAITING
Safeguarding children from institutional harm
Unqualified "safe" and "evidence-based" claims
Kaleido's website describes gender-affirming care as "safe," "evidence-based," and "best-practice" without disclosing that multiple independent systematic reviews (Cass 2024, York 2024, US HHS 2025) found low to very-low certainty evidence for key outcomes. Claiming treatments are "safe" and "evidence-based" while omitting evidence limitations is misleading advertising under Section 133 of the National Law.
What's missing
-
No disclosure that evidence for mental health benefits is low/very-low certainty
-
No disclosure that long-term safety data are limited or absent
-
No disclosure that "safe" claims rest on sparse harms reporting, not proof of safety
-
No caveats that the evidence is largely observational, short-term, or based on studies that compare results before and after an intervention, without strong evidence that the intervention itself caused the change.
The legal issue
Section 133 prohibits creating false impressions about treatment safety or efficacy. When systematic reviews consistently find low certainty evidence, describing treatments without qualification as "safe" and "evidence-based" is materially misleading.
Evidence detail
What the audit says "Complete absence of risk disclosure on public website, despite offering 'Gender Affirming Hormone Therapy' as a current service. No mention of cardiovascular risks, bone health risks, fertility impairment, sexual function impacts, cancer risks, liver damage risks, or irreversibility of certain effects." —Kaleido Health Centre Informed Consent Compliance Audit, Section 3 (8 May 2026)
Assessment criteria The audit assessed the clinic's website against: • Australian Consumer Law sections 18 and 29 • Health Practitioner Regulation National Law section 133 • Independent systematic reviews establishing what risks are material (Cass 2024, York/ADC 2024, US HHS 2025, Ruuska 2026)
For Parents
What this means for you
"Evidence-based" doesn't mean "proven safe and effective." It can also mean "we have some evidence, but it's low quality and we're uncertain."
Kaleido uses the phrase without explaining what the evidence actually shows.
For Mps
Policy & regulatory issue
The clinic benefits from the halo of "evidence-based medicine" while concealing that the evidence base is weak, short-term, and uncertain.
For Health Professionals
Clinical & professional standards issue
The gap between "evidence-based" (technically true—there is some evidence) and what a reasonable consumer understands (strong, reliable evidence of benefit) is the compliance failure. Standards require honest characterisation of evidence quality.
Evidence detail
This connects to other compliance failures documented in the audit:
-
Finding 1: Overall Impression — Systematic omission across all pages creates misleading overall impression
-
Findings 5 & 6: Irreversibility & Fertility — No disclosure of permanent effects or fertility impacts despite offering hormones